AustralieFrV1, PascalFrancis, Curation, bibRecord, 000546

The palliative effects of octreotide in cancer patients

Identifieur interne : 000546 ( PascalFrancis/Curation ); précédent : 000545; suivant : 000547

The palliative effects of octreotide in cancer patients

Auteurs : Andrew Dean [Australie]

Source :

Chemotherapy : (Basel) [ 0009-3157 ] ; 2001.

RBID : Pascal:01-0243004

Descripteurs français

Pascal (Inist)
- Octréotide, Somatostatine, Analogue, Homme, Tumeur maligne, Traitement, Anticancéreux, Chimiothérapie, Traitement palliatif, Douleur, Analgésie, Occlusion, Intestin, Diarrhée, Fistule, Neuropeptide.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Analgesia, Analog, Antineoplastic agent, Chemotherapy, Diarrhea, Fistula, Gut, Human, Malignant tumor, Neuropeptide, Occlusion, Octreotide, Pain, Palliative treatment, Somatostatin, Treatment.

Abstract

Octreotide is an extremely useful compound for palliative care physicians. It appears to be active in a number of different pain states and may be given by the spinal and intraventricular route. Its actions in reducing gut motility and secretions make it a valuable adjunct in the management of inoperable bowel obstruction. The same actions make it a potent antidiarrheal agent. Octreotide will often succeed where other antidiarrheal agents fail. Its ability to reduce gut secretions has led to its use in the treatment of fistulae. It has also been proposed as a useful drug in the management of cachexia and ascites. Most of the existing evidence is based on small numbers of case reports and further larger trials are necessary.

A01	`01`	`1`		`@0 0009-3157`
A02	`01`			`@0 CHTHBK`
A03		`1`		`@0 Chemotherapy : (Basel)`
A05				`@2 47`
A06				`@3 SUP2`
A08	`01`	`1`	`ENG`	`@1 The palliative effects of octreotide in cancer patients`
A09	`01`	`1`	`ENG`	`@1 Somatostatin analogs in cancer management`
A11	`01`	`1`		`@1 DEAN (Andrew)`
A12	`01`	`1`		`@1 SCARPIGNATO (Carmelo) @9 ed.`
A14	`01`			`@1 Palliative Care Service, Sir Charles Gairdner Hospital @2 Nedlands @3 AUS @Z 1 aut.`
A15	`01`			`@1 University of Parma @3 ITA @Z 1 aut.`
A15	`02`			`@1 University of Nantes @3 FRA @Z 1 aut.`
A20				`@1 54-61`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 1189 @5 354000098056570040`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 54 ref.`
A47	`01`	`1`		`@0 01-0243004`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Chemotherapy : (Basel)`
A66	`01`			`@0 CHE`
C01	`01`		`ENG`	@0 Octreotide is an extremely useful compound for palliative care physicians. It appears to be active in a number of different pain states and may be given by the spinal and intraventricular route. Its actions in reducing gut motility and secretions make it a valuable adjunct in the management of inoperable bowel obstruction. The same actions make it a potent antidiarrheal agent. Octreotide will often succeed where other antidiarrheal agents fail. Its ability to reduce gut secretions has led to its use in the treatment of fistulae. It has also been proposed as a useful drug in the management of cachexia and ascites. Most of the existing evidence is based on small numbers of case reports and further larger trials are necessary.
C02	`01`	`X`		`@0 002B02R02`
C03	`01`	`X`	`FRE`	`@0 Octréotide @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Octreotide @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Octreotida @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Somatostatine @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Somatostatin @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Somatostatina @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Analogue @5 07`
C03	`03`	`X`	`ENG`	`@0 Analog @5 07`
C03	`03`	`X`	`SPA`	`@0 Análogo @5 07`
C03	`04`	`X`	`FRE`	`@0 Homme @5 10`
C03	`04`	`X`	`ENG`	`@0 Human @5 10`
C03	`04`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`05`	`X`	`FRE`	`@0 Tumeur maligne @5 11`
C03	`05`	`X`	`ENG`	`@0 Malignant tumor @5 11`
C03	`05`	`X`	`SPA`	`@0 Tumor maligno @5 11`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 12`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 12`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 12`
C03	`07`	`X`	`FRE`	`@0 Anticancéreux @5 13`
C03	`07`	`X`	`ENG`	`@0 Antineoplastic agent @5 13`
C03	`07`	`X`	`SPA`	`@0 Anticanceroso @5 13`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 14`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 14`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 14`
C03	`09`	`X`	`FRE`	`@0 Traitement palliatif @5 15`
C03	`09`	`X`	`ENG`	`@0 Palliative treatment @5 15`
C03	`09`	`X`	`SPA`	`@0 Tratamiento paliativo @5 15`
C03	`10`	`X`	`FRE`	`@0 Douleur @5 16`
C03	`10`	`X`	`ENG`	`@0 Pain @5 16`
C03	`10`	`X`	`SPA`	`@0 Dolor @5 16`
C03	`11`	`X`	`FRE`	`@0 Analgésie @5 17`
C03	`11`	`X`	`ENG`	`@0 Analgesia @5 17`
C03	`11`	`X`	`SPA`	`@0 Analgesia @5 17`
C03	`12`	`X`	`FRE`	`@0 Occlusion @5 18`
C03	`12`	`X`	`ENG`	`@0 Occlusion @5 18`
C03	`12`	`X`	`SPA`	`@0 Oclusión @5 18`
C03	`13`	`X`	`FRE`	`@0 Intestin @5 19`
C03	`13`	`X`	`ENG`	`@0 Gut @5 19`
C03	`13`	`X`	`SPA`	`@0 Intestino @5 19`
C03	`14`	`X`	`FRE`	`@0 Diarrhée @5 20`
C03	`14`	`X`	`ENG`	`@0 Diarrhea @5 20`
C03	`14`	`X`	`SPA`	`@0 Diarrea @5 20`
C03	`15`	`X`	`FRE`	`@0 Fistule @5 21`
C03	`15`	`X`	`ENG`	`@0 Fistula @5 21`
C03	`15`	`X`	`SPA`	`@0 Fístula @5 21`
C03	`16`	`X`	`FRE`	`@0 Neuropeptide @5 22`
C03	`16`	`X`	`ENG`	`@0 Neuropeptide @5 22`
C03	`16`	`X`	`SPA`	`@0 Neuropéptido @5 22`
N21				`@1 169`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005C11

Links to Exploration step

Pascal:01-0243004

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The palliative effects of octreotide in cancer patients</title>
<author><name sortKey="Dean, Andrew" sort="Dean, Andrew" uniqKey="Dean A" first="Andrew" last="Dean">Andrew Dean</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Palliative Care Service, Sir Charles Gairdner Hospital</s1>
<s2>Nedlands</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0243004</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0243004 INIST</idno>
<idno type="RBID">Pascal:01-0243004</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005C11</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000546</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The palliative effects of octreotide in cancer patients</title>
<author><name sortKey="Dean, Andrew" sort="Dean, Andrew" uniqKey="Dean A" first="Andrew" last="Dean">Andrew Dean</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Palliative Care Service, Sir Charles Gairdner Hospital</s1>
<s2>Nedlands</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Chemotherapy : (Basel)</title>
<title level="j" type="abbreviated">Chemotherapy : (Basel)</title>
<idno type="ISSN">0009-3157</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Chemotherapy : (Basel)</title>
<title level="j" type="abbreviated">Chemotherapy : (Basel)</title>
<idno type="ISSN">0009-3157</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analgesia</term>
<term>Analog</term>
<term>Antineoplastic agent</term>
<term>Chemotherapy</term>
<term>Diarrhea</term>
<term>Fistula</term>
<term>Gut</term>
<term>Human</term>
<term>Malignant tumor</term>
<term>Neuropeptide</term>
<term>Occlusion</term>
<term>Octreotide</term>
<term>Pain</term>
<term>Palliative treatment</term>
<term>Somatostatin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Octréotide</term>
<term>Somatostatine</term>
<term>Analogue</term>
<term>Homme</term>
<term>Tumeur maligne</term>
<term>Traitement</term>
<term>Anticancéreux</term>
<term>Chimiothérapie</term>
<term>Traitement palliatif</term>
<term>Douleur</term>
<term>Analgésie</term>
<term>Occlusion</term>
<term>Intestin</term>
<term>Diarrhée</term>
<term>Fistule</term>
<term>Neuropeptide</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Octreotide is an extremely useful compound for palliative care physicians. It appears to be active in a number of different pain states and may be given by the spinal and intraventricular route. Its actions in reducing gut motility and secretions make it a valuable adjunct in the management of inoperable bowel obstruction. The same actions make it a potent antidiarrheal agent. Octreotide will often succeed where other antidiarrheal agents fail. Its ability to reduce gut secretions has led to its use in the treatment of fistulae. It has also been proposed as a useful drug in the management of cachexia and ascites. Most of the existing evidence is based on small numbers of case reports and further larger trials are necessary.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-3157</s0>
</fA01>
<fA02 i1="01"><s0>CHTHBK</s0>
</fA02>
<fA03 i2="1"><s0>Chemotherapy : (Basel)</s0>
</fA03>
<fA05><s2>47</s2>
</fA05>
<fA06><s3>SUP2</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The palliative effects of octreotide in cancer patients</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Somatostatin analogs in cancer management</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>DEAN (Andrew)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>SCARPIGNATO (Carmelo)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Palliative Care Service, Sir Charles Gairdner Hospital</s1>
<s2>Nedlands</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>University of Parma</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>University of Nantes</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s1>54-61</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>1189</s2>
<s5>354000098056570040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>54 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0243004</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Chemotherapy : (Basel)</s0>
</fA64>
<fA66 i1="01"><s0>CHE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Octreotide is an extremely useful compound for palliative care physicians. It appears to be active in a number of different pain states and may be given by the spinal and intraventricular route. Its actions in reducing gut motility and secretions make it a valuable adjunct in the management of inoperable bowel obstruction. The same actions make it a potent antidiarrheal agent. Octreotide will often succeed where other antidiarrheal agents fail. Its ability to reduce gut secretions has led to its use in the treatment of fistulae. It has also been proposed as a useful drug in the management of cachexia and ascites. Most of the existing evidence is based on small numbers of case reports and further larger trials are necessary.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Octréotide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Octreotide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Octreotida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Somatostatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Somatostatin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Somatostatina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Analogue</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Analog</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Análogo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement palliatif</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Palliative treatment</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento paliativo</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Douleur</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pain</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Dolor</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Analgésie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Analgesia</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Analgesia</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Occlusion</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Occlusion</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Oclusión</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Intestin</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Gut</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Intestino</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Diarrhée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Diarrhea</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Diarrea</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Fistule</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Fistula</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Fístula</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Neuropeptide</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Neuropeptide</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Neuropéptido</s0>
<s5>22</s5>
</fC03>
<fN21><s1>169</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000546 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000546 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0243004
   |texte=   The palliative effects of octreotide in cancer patients
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

The palliative effects of octreotide in cancer patients

The palliative effects of octreotide in cancer patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri